Neurogene (NGNE) Share-based Compensation (2013 - 2026)
Neurogene (NGNE) posted Share-based Compensation of $3.6 million for Q1 2026, up 189.65% on a QoQ basis from -$4.0 million in Q2 2025, and down 10.35% year-over-year from $4.0 million in Q1 2025.
Neurogene (NGNE) Share-based Compensation (2013 - 2026) Analysis & Trends
Neurogene's Share-based Compensation history runs 14 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- Quarterly Share-based Compensation fell 10.35% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$419000.0 (down 110.35% YoY) and the FY2024 annual result came in at $60000.0, down 95.77% from the prior year.
- Share-based Compensation was $3.6 million for Q1 2026 at Neurogene, up from -$4.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.8 million in Q3 2024 and bottomed at -$5.8 million in Q4 2024.
- A 5-year average of $454214.3 and a median of $709000.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 1726.2% — and 2025, when it soared 6646.67%.
- Neurogene's Share-based Compensation stood at -$5.5 million in 2022, then jumped by 106.41% to $355000.0 in 2023, then plunged by 1726.2% to -$5.8 million in 2024, then rose by 29.88% to -$4.0 million in 2025, then soared by 189.65% to $3.6 million in 2026.
- Business Quant data shows NGNE's Share-based Compensation at $3.6 million in Q1 2026, -$4.0 million in Q2 2025, and $4.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | 3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.63 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Mar 31, 2025 | 4.05 Mn |
| Mar 31, 2025 | 4.05 Mn |
| Dec 31, 2024 | -5.77 Mn |
| Dec 31, 2024 | -5.77 Mn |
| Sep 30, 2024 | 5.77 Mn |
| Sep 30, 2024 | 5.77 Mn |
| Mar 31, 2024 | 60,000.00 |
| Mar 31, 2024 | 60,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | -293,000.00 |
| Jun 30, 2023 | -293,000.00 |
| Mar 31, 2023 | 293,000.00 |
| Mar 31, 2023 | 293,000.00 |